Boston Sci sells Prolieve tech back to Medifocus for $5M

After marketing the device for three years, Boston Scientific ($BSX) has sold Prolieve back to Medifocus for $5 million. Boston Sci acquired the prostate gland-treating tech for $60 million in 2009, and Medifocus regains all Prolieve inventory, the device's patents and its related mobile distribution assets. Under the terms of the deal, Medifocus will pay Boston Sci $2.5 million upfront, followed by up to $2.5 million more in quarterly installments, depending on sales of the device. The companies expect to close the deal within 30 days. Release | More

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.